Clinical guidelines


The Therapeutic Goods Administration (TGA), with the support of the NSW, Victorian and Queensland state governments, commissioned a team to review the available scientific evidence for the use of cannabis medicines in five areas: palliative care, nausea and vomiting, epilepsy, multiple sclerosis and pain.

The NSW Government supported the review to provide a source of credible information about the available evidence to support medical practitioners considering the use of a cannabis medicine for their patient.

Advice developed for medical practitioners includes:

Prescribing guidance 

The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), based at the University of Newcastle, received funding from the NSW Government to develop practical NSW Cannabis Medicines Prescribing Guidance. 

Prescribing Guidance documents have been developed to provide interim information to support NSW medical practitioners in prescribing cannabis medicines to patients for conditions where cannabinoids are perceived to have some benefit. These are available on ACRE’s website.